Department of Medical Oncology, Althaia Xarxa Assistencial Universitària de Manresa, Dr. Joan Soler, 1-3, 08243 Manresa, Spain.
Programa de Doctorat en Medicina i Recerca Translacional, Facultat de Medicina, Universitat de Barcelona, 08036 Barcelona, Spain.
Int J Mol Sci. 2024 Aug 31;25(17):9506. doi: 10.3390/ijms25179506.
Melanoma is the most aggressive and deadly form of skin cancer, and its incidence has been steadily increasing over the past few decades, particularly in the Caucasian population. Immune checkpoint inhibitors (ICI), anti-PD-1 monotherapy or in combination with anti-CTLA-4, and more recently, anti-PD-1 plus anti-LAG-3 have changed the clinical evolution of this disease. However, a significant percentage of patients do not benefit from these therapies. Therefore, to improve patient selection, it is imperative to look for novel biomarkers. Immune subsets, particularly the quantification of lymphocyte T populations, could contribute to the identification of ICI responders. The main purpose of this review is to thoroughly examine significant published data on the potential role of lymphocyte T subset distribution in peripheral blood (PB) or intratumorally as prognostic and predictive of response biomarkers in advanced melanoma patients treated with ICI regardless of BRAFV600 mutational status.
黑色素瘤是最具侵袭性和致命性的皮肤癌，在过去几十年中，其发病率一直在稳步上升，尤其是在白种人群中。免疫检查点抑制剂（ICI）、抗 PD-1 单药治疗或与抗 CTLA-4 联合治疗，以及最近的抗 PD-1 联合抗 LAG-3，改变了这种疾病的临床演变。然而，相当一部分患者并未从这些治疗中获益。因此，为了改善患者选择，寻找新的生物标志物势在必行。免疫亚群，特别是淋巴细胞 T 群的定量分析，可能有助于识别 ICI 应答者。本综述的主要目的是彻底检查已发表的关于淋巴细胞 T 亚群在晚期黑色素瘤患者外周血（PB）或肿瘤内分布作为预后和预测对 ICI 治疗有反应的生物标志物的潜在作用的重要数据，无论 BRAFV600 突变状态如何。
